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Abstract
Background: Tardive dyskinesia is a disorder characterized by involuntary muscle movements that occur as a complication of 
long-term treatment with antipsychotic drugs. It has been suggested to be related to a malfunctioning of the indirect pathway of 
the motor part of the cortical-striatal-thalamic-cortical circuit, which may be caused by oxidative stress-induced neurotoxicity.
Methods: The purpose of our study was to investigate the possible association between phosphatidylinositol-4-phosphate-
5-kinase type IIa (PIP5K2A) function and tardive dyskinesia in 491 Caucasian patients with schizophrenia from 3 different 
psychiatric institutes in West Siberia. The Abnormal Involuntary Movement Scale was used to assess tardive dyskinesia. 
Individuals were genotyped for 3 single nucleotide polymorphisms in PIP5K2A gene: rs10828317, rs746203, and rs8341.
Results: A significant association was established between the functional mutation N251S-polymorphism of the PIP5K2A gene 
(rs10828317) and tardive dyskinesia, while the other 2 examined nonfunctional single nucleotide polymorphisms were not related.
Conclusions: We conclude from this association that PIP5K2A is possibly involved in a mechanism protecting against tardive 
dyskinesia-inducing neurotoxicity. This corresponds to our hypothesis that tardive dyskinesia is related to neurotoxicity at 
striatal indirect pathway medium-sized spiny neurons.
Keywords: PIP5K2A, schizophrenia, tardive dyskinesia, gene polymorphism, medium spiny neurons, neurotoxicity
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Introduction
Dyskinesia is a collective name for a variety of involuntary hyper-
kinetic movements (Loonen and Van Praag, 2007). The move-
ments are irregular, repetitive, and typically include motionless 
intervals. Dyskinesia may result from long-term treatment with 
antipsychotic drugs. This involuntary movement syndrome is 
termed tardive dyskinesia (TD) (Margolese et  al., 2005; Kane, 
2006). TD is a potentially disabling irreversible movement dis-
order, which has a prevalence of around 30% in patients chroni-
cally exposed to antipsychotics (Kane et al., 1988; Glazer, 2000). 
It can be subdivided into orofaciolingual (TDof) and limb-truncal 
(TDlt) dyskinesia (Al Hadithy et al., 2009, 2010).
TD is classified as an extrapyramidal movement disorder 
and may be related to a malfunctioning of the indirect pathway 
of the motor part of the cortical-striatal-thalamic-cortical cir-
cuit (Figure 1) (Loonen and Ivanova, 2013). The indirect pathway 
starts with dopamine-D2 receptor expressing medium-sized 
spiny neurons (MSNs) in the striatum. Activation of this path-
way results in inhibition of motor parts of the frontal cerebral 
cortex, and malfunctioning of this circuit would result in disin-
hibition and therefore hyperkinesia (Loonen and Ivanova, 2013).
Recently, our group identified an important link between 
2 other hyperkinetic extrapyramidal movement disorders: 
Huntington’s disease (HD) and Levodopa-induced dyskinesia 
(LID). Patients suffering from LID are more often carriers of the 
same variants of the GRIN2A gene as are determining an earlier 
age of onset of dyskinesia in HD patients (Ivanova et al., 2012). 
The GRIN2A gene encodes for the NR2A subunit of the gluta-
matergic  N-methyl-d-aspartate (NMDA) receptor (Paoletti and 
Neyton, 2007; Ivanova et al., 2012). In HD, symptoms are linked 
to NMDA receptor-induced excitotoxicity in indirect pathway 
MSNs (Estrada Sanchez et  al., 2007; Fan and Raymond, 2007; 
Kumar et al., 2010). Our finding suggests that LID is related to a 
similar NMDA receptor-related malfunctioning of dopamine-D2 
receptor carrying indirect pathway MSNs as HD. According to 
the neurotoxicity theory of TD, degeneration of indirect path-
way MSNs in this disorder is related to neurotoxic effects of the 
free radicals produced by excessive metabolism of dopamine 
(Lohr et al., 2003). This theory suggests that antipsychotic drugs 
block dopamine D2 receptors and therefore trigger a compensa-
tory release of excess dopamine. This excess requires increased 
metabolism of the spilled neurotransmitter. Increased dopamine 
metabolism releases high levels of hydrogen peroxide, which 
results in the production of free radicals, which then cause cell 
damage. Hence, excessive dopamine metabolism results in the 
production of more free radicals than the cell can handle. This 
hypothesis is consistent with the reported association between 
the incidence of TD and the presence of variants in the gene 
that encodes manganese superoxidedismutase, an enzyme that 
scavenges free radicals (Al Hadithy et al., 2010). A reduction in 
manganese superoxidedismutase activity would increase the 
likelihood of neurotoxic effects. It can be concluded that HD, LID, 
and TD are related to neurotoxic damage of indirect pathway 
MSNs and that every factor that increases neurotoxicity may 
also increase the likelihood of their becoming symptomatic.
Phosphatidylinositol 4-phosphate 5-kinase (PIP5K; EC 
2.7.1.68) is a neuronal intracellular enzyme that produces 
phosphatidylinositol (4,5)-biphosphate, which is catalyzed 
by phospholipase C to the second messengers inositol (1,4,5) 
triphosphate and diacylglycerol (for review, see Van den Bout 
and Divecha, 2009). Three isoforms of this enzyme have been 
identified: PIP5Kα, PIP5Kβ, and PIP5Kγ. The PIP5Kα isoform is 
also known as phosphatidylinositol-4-phosphate-5-kinase type 
IIa (PIP5K2A) and localizes to the plasma membrane and the 
Golgi complex and in the nucleus. PIP5K2A is involved in many 
different processes, including signal transduction of G-protein-
coupled receptors, cell survival by protection against apoptosis, 
and the genetic response to oxidative stress (Van den Bout and 
Divecha, 2009). The PIP5K2A gene has been shown to be associ-
ated with schizophrenia in several independent studies (Schwab 
et al., 2006; Bakker et al., 2007; He et al., 2007; Saggers-Gray et al., 
2008; Fedorenko et al., 2013). This is possibly related to a similar 
direct vs indirect pathway MSN hyperactivity explaining posi-
tive psychotic symptoms in schizophrenia as well as dyskine-
sia in TD. Indeed, drug-naïve first-episode patients experience 
spontaneous dyskinesia more frequently than healthy controls 
(Tenback and Van Harten, 2011).
Although the exact regulatory functions of different types 
of PIP5Ks are far from evident, these enzymes can be expected 
to also play a role in augmenting or decreasing the excitability 
of corticostriatal glutamatergic synapses with MSNs during the 
induction of long-term potentiation and long-term depression 
(LTD), respectively. Long-term potentiation and LTD may play an 
important role in the mechanism of dyskinesia, as they regulate 
Figure 1. The cortical-striatal-thalamic-cortical circuits, including the indirect and 
direct pathways. Activation of the direct pathway causes hyperkinesia and acti-
vation of the indirect pathway causes hypokinesia. ENK, enkephalin; GPe, globus 
pallidus, external segment; GPi, globus pallidus, internal segment; SNc, substantia 
nigra, pars compacta; SNr, substantia nigra, pars reticulata; SP/DYN,  substance 
P/dynorphin; STh, subthalamic nucleus; D1, D2, medium-sized spiny neurons 
(MSNs) with D1 or D2 receptors. Red, excitatory (glutamatergic, dopaminergic); 
blue, inhibitory (GABAergic, dopaminergic).
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the readiness of corticostriatal synapses to excitatory (includ-
ing excitotoxic) effects (Ivanova et al., 2012). In mice, for exam-
ple, NMDA receptor-mediated compensatory LTD depends upon 
activation of PIP5Kγ661, which results in AMPA receptor endocy-
tosis (Unoki et al., 2012).
In a heteromeric expression system, PIP5K2A has been 
disclosed to be a novel signaling element in the regulation of 
the neuronal KCNQ2/KCNQ3 and KCNQ3/KCNQ5 channels, 
EAAT3 glutamate transporter, and GluA1 function (Fedorenko 
et al., 2008, 2009; Seebohm et al., 2014). It has been shown that 
PIP5K2A regulation is disrupted in the schizophrenia-associated 
mutant (N251S)-PIP5K2A (rs10828317), which may contribute to 
the pathogenesis of schizophrenia through uncontrolled dopa-
minergic firing and deranged glutamate metabolism in the brain 
of schizophrenic patients carrying this mutation (Fedorenko 
et al., 2008, 2009; Seebohm et al., 2014).
We decided to study a possible association between a genetic 
variant of PIP5K2A encoding—according to in vitro observations 
(Fedorenko et al., 2008, 2009; Seebohm et al., 2014)—for a less active 
variant of this enzyme in comparison to 2 nonfunctional genetic 
variations and the prevalence of TD in a White Siberian patient 
population suffering from schizophrenia in order to establish a 
possible role for PIP5K in the pathophysiology of this disorder.
Patients and Methods
Patients
The work described in this article was carried out in accordance 
with the most recent version of the Code of Ethics of the World 
Medical Association (Declaration of Helsinki) for experiments 
involving humans and with the Uniform Requirements for manu-
scripts submitted to biomedical journals. After obtaining approval 
of the study protocol by the institutional bioethics committee, 
suitable participants were recruited from 3 psychiatric hospitals in 
the Tomsk, Kemerovo, and Chita areas in Siberia (Russia). All sub-
jects gave informed consent after proper explanation of the study.
We included 491 subjects with a clinical diagnosis of schiz-
ophrenia the 10th revision of the International Statistical 
Classification of Diseases and Related Health Problems (ICD-10: 
F20; N  =  465; 94.7%) or schizotypal disorder (ICD-10: F21) and 
excluded subjects with non-Caucasian physical appearance 
(eg, Mongoloid, Buryats, Tyvans, or Khakassians) or those with 
organic or neurological disorders. Patients were assessed for the 
presence or absence of dyskinesia according to the abnormal 
involuntary movement scale (AIMS) (Loonen and Van Praag, 2007). 
The AIMS scores were transformed into a binary form (presence 
or absence of dyskinesia) with Schooler and Kane (1982) criteria. 
The presence of TDof and TDlt was established by a cutoff score 
of ≥2 (mild but definite) on any of the items 1 through 4 and 5 
through 7 of AIMS, respectively. The sum of the first 4 items was 
used as a proxy for the severity of TDof, while the sum of items 5 
thru 7 was used as a proxy for the severity of TDlt.
A blood sample was taken for DNA isolation and genotyping. 
The other inclusion criteria were no addictions, no organic dis-
orders, and a high-quality DNA sample.
Medication
On the day of TD assessment, a complete documentation of 
the medications utilized was compiled by the raters. For com-
parison, daily antipsychotic medication dosages were con-
verted into chlorpromazine equivalents (Andreasen et  al., 
2010). Patients using clozapine who did not suffer from TD 
were excluded, as clozapine may suppress the symptoms of 
TD.
Genotyping
DNA extraction was conducted according to standard protocols 
using phenol-chloroform extraction. Genotyping of PIP5K2A pol-
ymorphisms (rs10828317, rs746203, rs8341) was performed on 
an ABI StepOnePlus with a TaqMan Validateе SNP Genotyping 
Assay (Applied Biosystems).
Statistics
The Hardy-Weinberg equilibrium of genotypic frequencies was 
tested by the chi-square test. Statistical analyses were per-
formed using SPSS software, release 17, for Windows; P < .05 
was considered as significant. To apply a correction for multi-
ple testing, we used algorithm for False Discovery Rate control, 
described by Benjamini and Hochberg (1995).
The chi-square test and the Fisher’s exact test, if necessary, 
were used for between-group comparisons of genotypic or allelic 
frequencies. Between-group differences in continuous variables 
were evaluated using the Student’s t test or 1-way analysis of 
variance. Comparisons of AIMS-score in different groups were 
carried out with the Kruskal Wallis test. The relevant Bonferroni 
correction for multiple testing was applied.
Logistic regression analysis was performed to isolate the 
possible TD-related variables: age, sex, duration of illness, age at 
onset, and PIP5K2A polymorphism.
Results
Table  1 shows the clinical and demographic characteristics of 
patients with and without TD. The genotype distribution of 
PIP5K2A (rs10828317, rs746203, rs8341) polymorphisms were 
in agreement with Hardy-Weinberg equilibrium in this patient 
group. No significant differences in genotype frequencies of the 2 
nonfunctional polymorphisms rs746203 and rs8341 between the 
2 groups of patients with and without TD were found (Table 2). 
However, a significant association was demonstrated to exist 
between TD and the functional rs10828317 mutation. After cor-
rection for multiple testing, the observed differences remained 
statistically significant (P = .018). CC carriers had a higher risk 
Table 1. The Clinical and Demographic Characteristics of Patients with and without TD
With TD Without TD p
Gender (M/F) 83/48 221/139 X = .158; P = .691*
Age (y, mean ± SD) 43.9 ± 14.5 39.3 ± 15.2 P = .003**
Age of onset (y, mean ± SD) 24.95 ± 8.8 24.98 ± 8.9 P = .978**
Duration of disorder (y, mean ± SD) 19 ± 13.7 14.3 ± 12.6 P = .000**
Abbreviation: TD, tardive dyskinesia.
*Chi-square test; **t test.
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of TDof (OR = 2.55, 95CI = 1.56–4.14, P = .0006), TDlt (OR = 1.85, 
95CI = 1.1–3.13, P = .04), and TDtot (OR = 2.17, 95CI = 1.34–3.51, 
P = .003). So, the frequency of CC-carriers is about twice as high 
in the group of schizophrenic patients with TD compared to the 
group without TD.
We also found an association between genotype and severity 
of TD. Patients who are CC carriers of rs10828317 had a signifi-
cantly (P < .02 Mann-Whitney with Bonferroni correction) higher 
mean AIMS TDtot and TDof score in comparison to those with 
the CT or TT genotype (data not shown).
Analysis of covariance with age, sex, duration of disease, and 
chlorpromazine equivalent incorporated as covariates showed 
that TD is significantly (P < .005) associated with the PIP5K2A 
(rs10828317) polymorphism (details not shown).
Using the binary logistic regression method, we revealed 
an association between the CC-genotype of rs10828317 and TD 
(P = .005), whereas the input of age (P = .329), sex (P = .956), dura-
tion of disease (P = .139), chlorpromazine equivalent (P = .683), 
and age of onset of the disorder (Р = .608) were not statistically 
significant for our model.
Discussion
In this study, we genotyped patients with and without TD with 
respect to 3 polymorphisms of the PIP5K2A gene. In Figure 2, the 
single nucleotide polymorphism positions are represented. Only 
one of them, rs10828317, is known to be a functional mutation. 
Replacement of T to C leads to a nonsynonymous amino-acid 
exchange (asparagine/serine) that causes an increased distance 
between 2 antiparallel helices from 3Å to 6Å and thereby inter-
feres with the function of the enzyme (Fedorenko et al., 2008).
We decided to study the PIP5K2A gene, because this gene 
has repeatedly been shown to be associated with schizophrenia 
(Schwab et al., 2006; Bakker et al., 2007; He et al., 2007; Saggers-
Gray et al., 2008), and the vulnerability to develop TD is related 
to the likelihood to develop positive symptoms of schizophre-
nia. In a previous study, we have confirmed this association in 
the presently studied Caucasian Siberian patients with schizo-
phrenia (Fedorenko et al., 2013), but now we also demonstrated 
a relationship with the prevalence of TD. Koning et al. (2011a, 
2011b) have described an association of TD with schizotypy in 
Figure 2. Representation of the single nucleotide polymorphism positions of 3 studied polymorphisms of the PIP5K2A gene (He et al., 2007).
Table 2. Distribution of rs10828317, rs8341, and rs746203 Genotypes and Alleles in Patients with and without TD
Patients with TD Patient without TD Intergroup comparison, chi-square test
rs10828317 Genotype, N (%) TT 44 (34.6) 144 (43.3) X = 10.306, P = .006
CT 48 (37.8) 139 (41.9)
CC 35 (27.6) 49 (14.8)
T 0.56 0.64
C 0.46 0.36
HWE X = 7.33, P = .007 X = 2.57, P = .11
rs8341 Genotype TT 14 (14.4) 41 (13.3) X = 0.615, P = .735
CT 49 (50.5) 146 (47.2)
CC 34 (35.1) 122 (39.5)
T 0.4 0.37
C 0.6 0.63
HWE X = 0.2952, P = .6719 X = 0.0669, P = .9016
rs746203 Genotype TT 33 (34.7) 118 (39.1) X = 0.8, P = .67
CT 45 (47.4) 139 (46)
CC 17 (17.9) 45 (14.9)
T 0.58 0.62
C 0.42 0.38
HWE X = 0.0593, P = .8307 X = 0.15, P = .7133
Abbreviation: TD, tardive dyskinesia.
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unaffected siblings of patients with nonaffective psychosis. 
Moreover, drug naïve first-episode patients sometimes show 
spontaneous dyskinesia (Tenback and Van Harten, 2011). 
Therefore, indirect evidence supports a possible role of genetic 
factors increasing the vulnerability to develop TD in patients 
with schizophrenia. Hereditary decreased activity of PIP5K 
might be one of them.
The present study did not address the mechanisms regulated 
by PIP5K2A and possibly contributing to the development of TD in 
carriers of the rs10828317 polymorphism. It is noteworthy, how-
ever, that PIP5K2A participates in the regulation of both glutamate 
receptor GluA1 (Seebohm et al., 2014) and glutamate carrier EAAT3 
(Fedorenko et al., 2009). Thus, PIP5K2A may both increase gluta-
mate sensitivity of neurons and terminate glutamate-induced 
excitation by accelerating clearance of glutamate from the synap-
tic cleft. It is tempting to speculate that deranged glutamate sen-
sitivity or abundance may foster the development of TD, as it may 
increase the vulnerability of indirect pathway MSNs for oxidative 
stress-induced neurotoxicity (Loonen and Ivanova, 2013).
In conclusion, the present observations reveal an association 
of PIP5K2A gene variants with TD and thus suggest a clinical 
significance of this kinase in the control of movement and/or 
neuronal survival.
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